After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

President-elect Donald Trump has put forward a formal pick for the top spot at the U.S. Food and Drug Administration. | ...

For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.

While Johnson & Johnson hopes to soon resolve more than 60,000 talc lawsuits with an $8 billion bankruptcy settlement in the ...

For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...

The new drug, Jazz Pharmaceuticals’ zanidatamab, has won an FDA accelerated approval for adults with previously treated ...

Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of ...

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...

In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr. may not rock the ...

As a council of outside experts prepares to meet Thursday to discuss AstraZeneca’s Andexxa, the FDA has flagged “major safety ...

While president-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...